Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
The FTC and seven states have moved to hold Martin Shkreli in contempt for allegedly breaching his lifetime ban on pharmaceutical industry activity.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Federal Trade Commission, joined by seven state regulators, filed a motion asking a federal judge to find former biotech executive Martin Shkreli in contempt. The filing alleges that Shkreli, popularly known as “Pharma Bro,” violated a lifetime ban that bars him from participating in any pharmaceutical‑industry activities. The motion specifically cites alleged actions that influenced biopharma stock prices, prompting the regulators to seek a formal contempt finding. Coverage of the contempt motion appears across a broad set of outlets. Bloomberg.com and CNBC also reported that the FTC and states say Shkreli violated his lifetime pharma ban.
The consistency of the headline across these sources underscores the regulators’ coordinated effort and the focus on alleged stock‑influencing conduct. The backdrop to this filing is Shkreli’s earlier lifetime prohibition from the pharmaceutical sector, imposed after prior regulatory actions that barred him from any industry involvement. That ban makes any direct or indirect participation in pharma‑related business, including attempts to sway market prices of biotech firms, a clear violation. The current allegation suggests Shkreli engaged in activities that could affect biopharma equities, thereby breaching the terms of his ban and prompting the FTC and state agencies to pursue contempt enforcement. The next procedural step will be a judicial hearing on the contempt motion.
Observers will watch for the judge’s ruling on whether Shkreli’s conduct meets the legal threshold for contempt. Further statements from the FTC or the participating states, as well as any response from Shkreli’s legal team, are expected to follow. The outcome could determine additional penalties or enforcement measures tied to the lifetime ban.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (87% supported) Updated 35d ago.
Quick answers
What does the lifetime pharma ban on Martin Shkreli prohibit?
The ban bars Shkreli from any involvement in the pharmaceutical industry, including activities that could influence biopharma companies or their stock prices, according to the FTC’s contempt filing.
Which agencies are seeking the contempt finding against Shkreli?
The Federal Trade Commission and seven unnamed state regulators are jointly filing the contempt motion, as reported by Quartz and other outlets.
What specific conduct is alleged to have triggered the contempt claim?
Regulators allege that Shkreli engaged in actions that influenced biopharma stock prices, which they say violates his lifetime ban on pharmaceutical industry involvement.
Coverage (20)
- FTC, states sue ‘pharma bro’ over industry trades Politico · 35d ago
- FTC seeks sanctions against Martin Shkreli over alleged pharma ban violations Fierce Pharma · 35d ago
- Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says Ars Technica · 35d ago
- Martin Shkreli Violated Lifetime Ban From Drug Industry, U.S. Says The New York Times · 35d ago
- ‘Pharma Bro’ Martin Shkreli has caught the attention of federal and state authorities again CNN · 35d ago
- FTC: ‘Pharma bro’ Shkreli violated lifetime industry ban, should be held in contempt The Hill · 35d ago
- FTC, States Ask Court to Hold ‘Pharma Bro’ Shkreli in Contempt for Trading Drug Stocks WSJ · 35d ago
- FTC and seven states seek contempt ruling against Shkreli over pharma ban The Guardian · 35d ago
- FTC targets Martin Shkreli over pharma stock trading and market commentary Investing.com · 35d ago
- FTC says ‘pharma bro’ Martin Shkreli repeatedly violated industry ban Financial Times · 35d ago
- FTC asks judge to find 'Pharma Bro' Martin Shkreli in contempt Yahoo · 35d ago
- ‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks MarketWatch · 35d ago
- FTC asks judge to find 'Pharma Bro' Martin Shkreli in contempt upi · 35d ago
- FTC Files Contempt Motion Against Martin Shkreli for Alleged Pharmaceutical Industry Involvement GeneOnline · 35d ago
- 'Pharma Bro' Martin Shkreli facing FTC contempt motion STAT · 35d ago
- FTC Seeks Contempt Finding Against Martin Shkreli Over Pharma Ban SuaraGarut.ID · 35d ago
- FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation Investing.com Nigeria · 35d ago
- FTC and 7 states are seeking to hold Martin Shkreli in contempt over pharma ban Quartz · 35d ago
- Shkreli Faces Contempt for Breaking Pharmaceutical Industry Ban Bloomberg.com · 35d ago
- Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim CNBC · 35d ago
Topics
Related trends
These Companies Are Using Trump’s Tariff Refunds for Executive Bonuses
Major retail and technology corporations are reportedly directing federal tariff refunds toward executive bonuses instead of consumer refunds.
Family Dollar agrees to $63M settlement in multistate lawsuit claiming retailer overcharged customers
Family Dollar agrees to a $63 million multistate settlement over allegations it routinely charged customers more than advertised shelf prices.
Family Dollar to pay $63m to settle overcharging allegations
Family Dollar will pay $63 million to settle FTC and multistate allegations that it routinely charged customers more at the register than advertised shelf prices.
Five US states join FTC suit against Hims & Hers over privacy practices
Five U.S. states joined the FTC's lawsuit against Hims & Hers on Tuesday, expanding a case that alleges the telehealth company shared sensitive health data with Meta and Snap and charged for prescriptions before provider consultations.
FTC and States Take Action Against Toast Inc. over Hidden and Unauthorized Fees, Deceptive Subscription and Cancellation Practices and Other Unlawful Conduct
Federal regulators and multiple state attorneys general have filed a major lawsuit against restaurant technology firm Toast Inc.
FTC probes whether major US companies charge customers different prices using personal data
The FTC opens a formal inquiry into algorithmic personalized pricing by major United States corporations.